MX354249B - Formas de dosificación farmacéuticas intranasales que comprenden naloxona. - Google Patents

Formas de dosificación farmacéuticas intranasales que comprenden naloxona.

Info

Publication number
MX354249B
MX354249B MX2013013276A MX2013013276A MX354249B MX 354249 B MX354249 B MX 354249B MX 2013013276 A MX2013013276 A MX 2013013276A MX 2013013276 A MX2013013276 A MX 2013013276A MX 354249 B MX354249 B MX 354249B
Authority
MX
Mexico
Prior art keywords
naloxone
pharmaceutical dosage
intranasal pharmaceutical
dosage forms
dosage form
Prior art date
Application number
MX2013013276A
Other languages
English (en)
Other versions
MX2013013276A (es
Inventor
Strang John
Oksche Alexander
Harris Stephen
Smith Kevin
Helene Jeanne Mottier Lucie
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44658496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX354249(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MX2013013276A publication Critical patent/MX2013013276A/es
Publication of MX354249B publication Critical patent/MX354249B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una forma de dosificación farmacéutica intranasal que comprende una unidad de dosificación que comprende naloxona o una sal de la misma aceptable desde el punto de vista farmacéutico en una cantidad de equivalente a = 0,5 mg de naloxona HCI disuelta en un líquido de aplicación de un volumen de = 250 µl. Además, tal forma de dosificación farmacéutica intranasal para uso en el tratamiento de sobredosis de opiáceos y/o al menos un síntoma de la misma.
MX2013013276A 2011-05-13 2012-05-11 Formas de dosificación farmacéuticas intranasales que comprenden naloxona. MX354249B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11166076 2011-05-13
PCT/EP2012/058792 WO2012156317A2 (en) 2011-05-13 2012-05-11 Intranasal pharmaceutical dosage forms comprising naloxone

Publications (2)

Publication Number Publication Date
MX2013013276A MX2013013276A (es) 2014-08-07
MX354249B true MX354249B (es) 2018-02-20

Family

ID=44658496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013276A MX354249B (es) 2011-05-13 2012-05-11 Formas de dosificación farmacéuticas intranasales que comprenden naloxona.

Country Status (37)

Country Link
US (8) US20150018379A1 (es)
EP (2) EP3320893A1 (es)
JP (3) JP6110367B2 (es)
KR (2) KR101698182B1 (es)
CN (2) CN107260672A (es)
AR (1) AR086391A1 (es)
AT (1) AT16553U1 (es)
AU (2) AU2012257785B2 (es)
BR (1) BR112013029126A2 (es)
CA (1) CA2835940C (es)
CO (1) CO6821959A2 (es)
CY (1) CY1120399T1 (es)
DE (1) DE202012013606U1 (es)
DK (2) DK2706982T4 (es)
ES (1) ES2661838T5 (es)
HK (1) HK1255428A1 (es)
HR (1) HRP20180233T1 (es)
HU (1) HUE036465T2 (es)
IL (1) IL229409B (es)
LT (1) LT2706982T (es)
ME (1) ME02958B (es)
MX (1) MX354249B (es)
MY (1) MY194947A (es)
NO (1) NO2706982T3 (es)
PH (2) PH12013502313A1 (es)
PL (1) PL2706982T3 (es)
PT (1) PT2706982T (es)
RS (1) RS57054B1 (es)
RU (2) RU2587051C2 (es)
SG (1) SG194927A1 (es)
SI (1) SI2706982T1 (es)
SM (1) SMT201800105T1 (es)
TR (1) TR201802716T4 (es)
TW (1) TWI486161B (es)
UA (1) UA110974C2 (es)
WO (1) WO2012156317A2 (es)
ZA (1) ZA201308280B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
MY194947A (en) * 2011-05-13 2022-12-27 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
HK1231370A1 (zh) * 2014-03-14 2017-12-22 欧皮安特制药有限公司 鼻用药物产品及其使用方法
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11135155B2 (en) * 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US20160008277A1 (en) * 2014-07-09 2016-01-14 Lightlake Therapeutics Inc. Co-packaged drug products
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
WO2017011326A1 (en) * 2015-07-10 2017-01-19 Sanjay Gupta Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene
WO2017049181A1 (en) * 2015-09-17 2017-03-23 Adapt Pharma Limited Nasal drug products and methods of their use
KR102453781B1 (ko) * 2016-06-24 2022-10-12 오피언트 파마슈티컬스, 인코퍼레이티드 알코올 사용 장애의 치료용 조성물, 장치 및 방법
JP7114570B2 (ja) * 2016-08-17 2022-08-08 ヒクマ・ファーマシューティカルズ・ユー・エス・エイ・インコーポレイテッド 液体ナロキソンスプレー
EP3946547B1 (en) 2019-03-26 2026-03-25 Pinova Therapeutics Inc. Devices and methods for delivering pharmaceutical compositions
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
CA3166250A1 (en) 2020-02-05 2021-08-12 Gregory G. Plucinski Drug products for intranasal administration and uses thereof
WO2021222545A1 (en) * 2020-04-29 2021-11-04 The Texas A&M University System Naloxone nanoparticle compositions and methods thereof
RS63725B1 (sr) 2020-05-18 2022-12-30 Orexo Ab Nova farmaceutska kompozicija za davanje leka
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
AU2022323269A1 (en) 2021-08-04 2024-02-29 Indivior Inc. Compositions and methods for the treatment of opioid overdose
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
GB9908921D0 (en) * 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
HRP20010926A2 (en) 1999-06-16 2003-04-30 Nastech Pharmaceutical Co Pharmaceutical formulations and methods comprising intranasal morphine
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US6284765B1 (en) 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
JP4898073B2 (ja) * 2000-07-31 2012-03-14 ニュコメデ ダンマルク アンパーツセルスカブ 鼻内投与用フェンタニル組成物
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US20060110333A1 (en) 2002-07-11 2006-05-25 Taiho Pharmaceutical Co., Ltd. Composition for nasal absorption
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
CN1575795A (zh) * 2003-06-25 2005-02-09 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔喷雾剂
GB2403711A (en) * 2003-07-07 2005-01-12 Gw Pharma Ltd Drug dispenser with controlled access
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
CN1726915B (zh) * 2004-07-27 2013-04-24 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔给药系统或组合物及其制备方法
WO2006016530A1 (ja) 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
EP1815295B1 (en) * 2004-11-09 2008-12-03 Koninklijke Philips Electronics N.V. Array of spatial light modulators and method of production of a spatial light modulator device
ZA200704869B (en) * 2004-12-23 2009-02-25 Roxro Pharma Inc Therapeutic compositions for intranasal administration of ketorolac
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
RU2344822C2 (ru) * 2006-04-05 2009-01-27 Алексей Валентинович Надеждин Способ лечения героиновой наркомании
CN101668544B (zh) 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
CN101678112B (zh) * 2007-01-19 2016-08-31 哈南亚有限公司 用于递送治疗剂的方法和组合物
WO2009040595A1 (en) 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
MY194947A (en) * 2011-05-13 2022-12-27 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
HK1231370A1 (zh) 2014-03-14 2017-12-22 欧皮安特制药有限公司 鼻用药物产品及其使用方法
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray

Also Published As

Publication number Publication date
SG194927A1 (en) 2013-12-30
AU2012257785B2 (en) 2016-04-14
HUE036465T2 (hu) 2018-07-30
CA2835940C (en) 2020-08-04
US20150126540A1 (en) 2015-05-07
ME02958B (me) 2018-07-20
LT2706982T (lt) 2018-05-25
US20240082149A1 (en) 2024-03-14
SMT201800105T1 (it) 2018-05-02
CO6821959A2 (es) 2013-12-31
EP2706982A2 (en) 2014-03-19
AU2012257785A1 (en) 2013-11-28
PH12013502313A1 (en) 2022-04-08
US20190374464A1 (en) 2019-12-12
AR086391A1 (es) 2013-12-11
ZA201308280B (en) 2014-07-30
WO2012156317A3 (en) 2013-05-10
ES2661838T5 (es) 2021-11-18
RU2587051C2 (ru) 2016-06-10
US20210338574A1 (en) 2021-11-04
NO2706982T3 (es) 2018-06-02
EP2706982B2 (en) 2021-03-10
DK2706982T4 (da) 2021-05-10
PH12016501342A1 (en) 2018-06-11
HRP20180233T1 (hr) 2018-06-01
KR20170010078A (ko) 2017-01-25
DK2706982T3 (en) 2018-03-12
BR112013029126A2 (pt) 2017-02-07
CN107260672A (zh) 2017-10-20
CN103764119A (zh) 2014-04-30
AT16553U1 (de) 2020-01-15
RU2013155479A (ru) 2015-06-20
WO2012156317A2 (en) 2012-11-22
AU2016204880B2 (en) 2017-11-23
MY194947A (en) 2022-12-27
JP6110367B2 (ja) 2017-04-05
KR101873174B1 (ko) 2018-06-29
US11020343B2 (en) 2021-06-01
SI2706982T1 (en) 2018-05-31
US11806428B2 (en) 2023-11-07
US20170304192A1 (en) 2017-10-26
NZ705933A (en) 2016-07-29
TR201802716T4 (tr) 2018-03-21
PH12016501342B1 (en) 2018-06-11
TWI486161B (zh) 2015-06-01
JP2016128453A (ja) 2016-07-14
IL229409A0 (en) 2014-01-30
US20150018379A1 (en) 2015-01-15
KR101698182B1 (ko) 2017-01-19
RS57054B1 (sr) 2018-05-31
CY1120399T1 (el) 2019-07-10
PL2706982T3 (pl) 2018-07-31
US20170231904A1 (en) 2017-08-17
RU2657441C1 (ru) 2018-06-13
DE202012013606U1 (de) 2018-04-18
US20260108456A1 (en) 2026-04-23
DK201800034U1 (da) 2018-05-25
JP2014513683A (ja) 2014-06-05
ES2661838T3 (es) 2018-04-04
EP2706982B1 (en) 2018-01-03
PT2706982T (pt) 2018-03-08
MX2013013276A (es) 2014-08-07
CA2835940A1 (en) 2012-11-22
AU2016204880A1 (en) 2016-07-28
KR20140007482A (ko) 2014-01-17
TW201311244A (zh) 2013-03-16
UA110974C2 (uk) 2016-03-10
JP2018150336A (ja) 2018-09-27
EP3320893A1 (en) 2018-05-16
NZ617442A (en) 2015-03-27
US12458591B2 (en) 2025-11-04
IL229409B (en) 2020-10-29
HK1255428A1 (en) 2019-08-16

Similar Documents

Publication Publication Date Title
MX354249B (es) Formas de dosificación farmacéuticas intranasales que comprenden naloxona.
CL2013001943A1 (es) Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma.
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
PT2601962T (pt) Regime de dosagem de lag-3 para utilização no tratamento de cancro
IL230819A0 (en) Refractory oral pharmaceutical dosage form containing an opioid agonist and an opioid antagonist
HK1211475A1 (en) Combination therapy
BR112013011480A2 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
CL2012003012A1 (es) Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion.
CL2013002905A1 (es) Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares.
CL2013001564A1 (es) Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica.
CL2012002437A1 (es) Uso de antiinflamatorio no esteroide (aine) o una sal farmacologicamente aceptable del mismo para preparar un medicamento util para el tratamiento de enfermedades renales cronicas en gatos.
CL2014002790A1 (es) Metodo de prevencion o tratamiento de la disfuncion intestinal inducida por oxicodona que comprende administrar buprenorfina concomitantemente con clorhidrato de oxicodona; unidad de dosis farmaceutica; kit que comprende una unidad de dosis de buprenorfina y otra de clorhidrato de oxicodona; sistema de buprenorfina transdermico.
CL2013003198A1 (es) Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas.
PH12016500666A1 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
MX2009005798A (es) Recuperacion de apoplejia.
PE20151543A1 (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso
BR112014001425A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo
CU20140028A7 (es) Compuesto de benzotiazolona
UA118656C2 (uk) Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції
EA201500368A1 (ru) Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии

Legal Events

Date Code Title Description
FG Grant or registration